Hamon F, Goeminne P
Clinique Ambroise Pare, Lille, France.
Semin Ophthalmol. 2001 Dec;16(4):223-32. doi: 10.1076/soph.16.4.223.10301.
The purpose of this paper is to evaluate photodynamic therapy (PDT) in the management of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) that converted from occult CNV to classic CNV after treatment with transpupillary thermotherapy (TTT). One hundred and fifty-four eyes of 130 patients with symptomatic occult CNV were treated between June 2000 and August 2001. We have analyzed data from patients treated with PDT because of a conversion from occult to classic CNV after TTT. The results were that twenty-four of 154 eyes developed a predominantly classic CNV; 20 eyes of 19 consecutive patients were treated with PDT with verteporfin. The mean follow-up period was 10 months. The mean delay for retreatment with TTT was 3 months; 3 eyes initially presented a pure occult CNV, 15 a minimally classic CNV, 1 an occult CNV with pigment epithelial detachment, and 1 a large macular subretinal hemorrhage with a subfoveal focal hot spot. The average classic component within a lesion before TTT was 20%. Recurrence of classic CNV was noted in the first 3 months for 14 eyes. Visual acuity improved in 5 eyes by >/=2 lines, and in 2 eyes by 1 line; 4 of 20 eyes had stabilized visual acuity; 7 eyes had a visual acuity decline of >/=2 lines; 2 eyes lost 1 line. All patients had reduction of metamorphopsia and reduction of exudation; 14 eyes had a little subretinal fibrosis and some partially atrophic areas; 6 eyes had slightly increased leakage in the late phase of the angiogram. In conclusion, association of TTT and PDT appears to be safe and may help practitioners to manage some difficult cases. This study seems to confirm the great efficacy of PDT in CNV with recent activity.
本文的目的是评估光动力疗法(PDT)在治疗年龄相关性黄斑变性(AMD)所致脉络膜新生血管(CNV)中的作用,这些CNV是经瞳孔温热疗法(TTT)治疗后从隐匿性CNV转变为典型性CNV的。2000年6月至2001年8月期间,对130例有症状的隐匿性CNV患者的154只眼进行了治疗。我们分析了因TTT后从隐匿性转变为典型性CNV而接受PDT治疗的患者的数据。结果显示,154只眼中有24只主要发展为典型性CNV;19例连续患者的20只眼接受了维替泊芬PDT治疗。平均随访期为10个月。TTT再次治疗的平均延迟时间为3个月;3只眼最初表现为单纯隐匿性CNV,15只为轻度典型性CNV,1只为伴有色素上皮脱离的隐匿性CNV,1只为伴有黄斑中心凹下局灶性热点的大片黄斑视网膜下出血。TTT治疗前病变内平均典型成分占20%。14只眼在最初3个月内出现典型性CNV复发。5只眼视力提高≥2行,2只眼提高1行;20只眼中4只眼视力稳定;7只眼视力下降≥2行;2只眼视力下降1行。所有患者的视物变形和渗出均减轻;14只眼有少许视网膜下纤维化和一些部分萎缩区域;6只眼在血管造影晚期渗漏略有增加。总之,TTT与PDT联合应用似乎是安全可行的,可能有助于医生处理一些疑难病例。本研究似乎证实了PDT对近期活动期CNV有显著疗效。